An Oral Cannabinoid Study Found Bronchial Effects Were Not Shared Equally by THC, CBD and CBN

A 1984 series of controlled oral-cannabinoid experiments found bronchodilator activity with THC-related conditions, but not effective bronchodilation from CBD, CBN or their tested combinations. The historical physiological findings do not establish an asthma treatment.

Experienced smokers received oral compounds

The double-blind experiments examined dose responses, combinations and repeated administration in experienced marijuana smokers. This was not a comparison of smoke inhalation with inhalers. The abstract reported no significant dose-related physiological effects for several tested compounds, while noting a delta-8 condition with bronchial, heart-rate and subjective effects smaller than delta-9 THC's.

A combination could affect one endpoint without another

Adding CBN or CBD to low-dose delta-9 THC did not produce significant bronchodilation but did show interactions in heart rate and reported high. Those results prevent treating an absence of one physiological effect as absence of all drug interaction.

The repeated-dose result was protocol-specific

A 20-day daily-administration comparison did not indicate tolerance or reverse tolerance on the reported outcomes. That finding cannot establish that these compounds never produce tolerance. Dose, prior cannabis experience, route and the particular physiological measure define its scope.

The study distinguishes chemical constituents rather than treating all cannabinoids as one drug. It does not demonstrate sustained respiratory benefit, symptom control or clinical safety for people with airway disease. A measured airway response and an effective treatment are different evidentiary claims.

Related: interpreting cannabis tolerance claims.

Research cited

Gong H; Tashkin DP; Simmons MS; Calvarese B; Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clinical pharmacology and therapeutics (1984). doi:10.1038/clpt.1984.4. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

A laboratory can identify a drug while relying on outside information to classify its prescription status. A national urine-testing study combined analytical results with medication information supplied by the ordering clinician. Two information streams McClure and colleagues analyzed 231,228 test-result sets from 144,535 patients tested for both opioids and benzodiazepines….

Spread the love

Read Article: How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

How Did a Stress-Management Trial Protocol Handle Medication Changes?

When a study evaluates psychological treatment, medication changes can complicate attribution of improvement. The 2017 Seren@ctif protocol described how investigators planned to address this issue in a trial of adjustment disorder with anxiety. The planned comparison Servant and colleagues proposed three randomized groups receiving computer-based stress management, an equivalent face-to-face…

Spread the love

Read Article: How Did a Stress-Management Trial Protocol Handle Medication Changes?

What Evidence Supports Extending Lipid Rescue to a Different Poison?

A treatment that appears useful for one toxicant raises a separate scientific question when proposed for another. Eisenkraft and Falk’s 2016 review of lipid emulsion and chemical-agent poisoning provides an example of that evidence gap. Several evidence types The authors discussed proposed lipid-scavenging, metabolic, and cardiovascular mechanisms. They reviewed laboratory…

Spread the love

Read Article: What Evidence Supports Extending Lipid Rescue to a Different Poison?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us